ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2470

Impaired Myocardial Flow Reserve on 82-Rubidium Positron Emission Tomography in Patients with Systemic Sclerosis
Abstract Number: 0417

Implementation of a Communication Aid in Juvenile Idiopathic Arthritis Patient Visits, a Quality Improvement Study
Abstract Number: 0373

Implementation of a Lupus Self-Management mHealth App: Using Incentives to Drive Engagement
Abstract Number: 1294

Implementation of Pneumococcal Vaccination in Patients with Childhood-Onset Systemic Lupus Erythematous
Abstract Number: 0520

Implementation of Salivary Gland Ultrasound by General Radiology can Improve Detection of Glandular Inflammation in Patients with Sicca
Abstract Number: 0205

Implementation of the Varicella Zoster virus vaccine and its Real-World effectiveness
Abstract Number: 1976

Implementing a Change Package for Depression Screening and Appropriate Response for Children with Rheumatic Disease
Abstract Number: 0448

Implementing Artificial Intelligence to Identify Rheumatoid Arthritis Flares Using Electronic Medical Records Processed with Privacy-Preserving Large Language Models: A Pilot Study
Abstract Number: 0408

Implementing Social Drivers of Health Screening for Patients with Pediatric Systemic Lupus Erythematosus
Abstract Number: 2274

Importance Of Fc Region On Therapeutic Survival In Rheumatoid Arthritis Patients With Anti-TNF Therapy
Abstract Number: 0803

Improved Efficacy and Safety Outcomes in Patients with SLE Treated with Belimumab (BEL) Versus Immunosuppressants (IS), in Addition to Antimalarials (AM) and Glucocorticoids (GC): A Post Hoc Summary of Five Phase 3 Trials
Abstract Number: 2256

Improved Outcomes of Acute Myocardial Infarction Among Patients with Rheumatoid Arthritis: A Propensity Matched National Study
Abstract Number: 0927

Improved Skin Lymphatic Flow Regulates Dendritic Cells to Mediate Lymph Node Fibroblast Alterations and Immune Responses in Lupus
Abstract Number: 1549

Improvement in Joint Activity in Adults with Systemic Lupus Erythematosus Treated with Anifrolumab: Results from a Real-World Cohort
Abstract Number: 0644

Improvement of Fatigue, Musculoskeletal Pain, and Morning Stiffness in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].